ATE456654T1 - Löslicher zytokinrezeptor zalpfa11 - Google Patents

Löslicher zytokinrezeptor zalpfa11

Info

Publication number
ATE456654T1
ATE456654T1 AT06011463T AT06011463T ATE456654T1 AT E456654 T1 ATE456654 T1 AT E456654T1 AT 06011463 T AT06011463 T AT 06011463T AT 06011463 T AT06011463 T AT 06011463T AT E456654 T1 ATE456654 T1 AT E456654T1
Authority
AT
Austria
Prior art keywords
methods
zalpfa11
vitro
vivo
cytokine receptor
Prior art date
Application number
AT06011463T
Other languages
English (en)
Inventor
Cindy A Sprecher
Julia E Novak
James West
Scott R Presnell
Richard D Holly
Andrew J Nelson
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE456654T1 publication Critical patent/ATE456654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
AT06011463T 2000-04-05 2001-04-03 Löslicher zytokinrezeptor zalpfa11 ATE456654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19473100P 2000-04-05 2000-04-05
US22212100P 2000-07-28 2000-07-28

Publications (1)

Publication Number Publication Date
ATE456654T1 true ATE456654T1 (de) 2010-02-15

Family

ID=26890341

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06011463T ATE456654T1 (de) 2000-04-05 2001-04-03 Löslicher zytokinrezeptor zalpfa11
AT01926604T ATE349522T1 (de) 2000-04-05 2001-04-03 Löslicher zytokinrezeptor zalpha11

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01926604T ATE349522T1 (de) 2000-04-05 2001-04-03 Löslicher zytokinrezeptor zalpha11

Country Status (9)

Country Link
US (9) US6777539B2 (de)
EP (2) EP1749888B1 (de)
AT (2) ATE456654T1 (de)
AU (1) AU2001253127A1 (de)
CA (1) CA2420992C (de)
DE (2) DE60125543T2 (de)
DK (2) DK1749888T3 (de)
ES (2) ES2339959T3 (de)
WO (1) WO2001077171A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2237915A1 (en) * 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
EP1787997A1 (de) * 2000-05-11 2007-05-23 Genetics Institute, LLC MU-1, ein Mitglied der cytokine rezeptor Familie
ATE540575T1 (de) * 2001-03-16 2012-01-15 Basf Plant Science Gmbh Regulatoren des zucker- und lipidstoffwechsels in pflanzen
ES2629395T3 (es) * 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
JP2005530716A (ja) * 2002-03-27 2005-10-13 アメリカ合衆国 ヒトにおける癌の治療方法
ES2381265T3 (es) 2002-06-07 2012-05-24 Zymogenetics, Inc. Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
MXPA05000655A (es) 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
AU2004221876B2 (en) * 2003-03-14 2011-05-26 Cambridge Antibody Technology Limited Antibodies against human IL-21 receptor and uses therefor
WO2004084835A2 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
EP1692276B1 (de) * 2003-11-19 2010-07-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b-zellen
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
DK1758610T3 (da) 2004-05-20 2012-10-15 Zymogenetics Inc Fremgangsmåder til behandling af cancer ved hjælp af IL-21 og monoklonal antistofterapi
US20060039902A1 (en) * 2004-08-05 2006-02-23 Young Deborah A Antagonizing interleukin-21 receptor activity
EP1807506B1 (de) * 2004-10-08 2013-04-17 Georgia Tech Research Corporation Mikroverkapselung von zellen in hydrogelen durch elektrostatische potentiale
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP1963369B1 (de) 2005-11-28 2013-05-15 Zymogenetics, Inc. Il-21-antagonisten
WO2007114861A2 (en) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
AU2007233092B2 (en) * 2006-03-31 2014-03-20 Karima Ferrani-Kile Methods and compositions for obtaining and using biologically active multi-protein complexes
KR101615215B1 (ko) * 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
CA2725154A1 (en) * 2008-05-23 2009-11-26 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
AR071885A1 (es) * 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP5252747B2 (ja) 2008-10-16 2013-07-31 Ｈｏｙａ Ｃａｎｄｅｏ Ｏｐｔｒｏｎｉｃｓ株式会社 偏光ガラス及びその製造方法並びに光アイソレーター
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
WO2012028740A1 (en) * 2010-09-03 2012-03-08 Confarma France Quantification of residual host cell dna by real-time quantitative pcr
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
JP2001508309A (ja) 1997-01-16 2001-06-26 ジェネティックス・インスチチュート・インコーポレーテッド ヘマトポイエチン受容体スーパーファミリーのメンバー
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2330547A1 (en) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor proteins
AU5104799A (en) * 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
KR20010085838A (ko) * 1998-09-23 2001-09-07 리스 데브라 케이. 사이토킨 리셉터 ｚａｌｐｈａ11
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
KR20010086005A (ko) 1998-11-06 2001-09-07 스타르크, 카르크 트리사이클릭 피라졸 유도체
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) * 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11

Also Published As

Publication number Publication date
US20040235743A1 (en) 2004-11-25
US20100074905A1 (en) 2010-03-25
DK1749888T3 (da) 2010-05-10
EP1303602A2 (de) 2003-04-23
US6777539B2 (en) 2004-08-17
ES2279809T3 (es) 2007-09-01
EP1749888B1 (de) 2010-01-27
ES2339959T3 (es) 2010-05-27
DE60125543D1 (de) 2007-02-08
US7189695B2 (en) 2007-03-13
US7763713B2 (en) 2010-07-27
WO2001077171A3 (en) 2002-05-16
CA2420992C (en) 2010-07-13
US7629452B2 (en) 2009-12-08
EP1749888A3 (de) 2007-03-14
US20110189207A1 (en) 2011-08-04
EP1749888A2 (de) 2007-02-07
ATE349522T1 (de) 2007-01-15
US20110003973A1 (en) 2011-01-06
AU2001253127A1 (en) 2001-10-23
DK1303602T3 (da) 2007-05-07
DE60141234D1 (de) 2010-03-18
US20070224118A1 (en) 2007-09-27
WO2001077171A2 (en) 2001-10-18
US20080032333A1 (en) 2008-02-07
EP1303602B1 (de) 2006-12-27
US20020137677A1 (en) 2002-09-26
US20090221802A1 (en) 2009-09-03
US20090196882A1 (en) 2009-08-06
DE60125543T2 (de) 2007-10-04
CA2420992A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
ATE456654T1 (de) Löslicher zytokinrezeptor zalpfa11
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
IL163067A (en) Isolated heterodimeric cytokine receptor
CY1118115T1 (el) Υποδοχεας κυτοκινης zcytor17
DK1356046T3 (da) Cytokinreceptor zcytoR19
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
DE69738066D1 (de) Hematopoietischer zytokin rezeptor
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
NZ510744A (en) Cytokine receptor zalpha11
DK0759942T3 (da) Interleukin-15-receptorer
WO2003089603A3 (en) Cytokine receptor
TR199901636T2 (xx) �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
DE69529674T2 (de) Biologisch aktive ligande der eph familie
EP1736545A3 (de) Lösliche Zcyctor 11 Cytokinrezeptoren
WO2003033665A3 (en) Secreted protein, ztnf9
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1749888

Country of ref document: EP